What top creators are saying about Eli Lilly and Company(LLY)— Page 2

Highlighted as an early adopter using AI agents to drive productivity and improve profit margins.

Specific pharma leader noted for being ripe for AI-driven disruption.

Building a $1 billion AI lab in San Francisco in partnership with NVIDIA to accelerate drug discovery.

Identified as the primary 'AI Pharma' play due to its data-driven approach to drug development.

Acquired Centessa; targeting the Orexin pathway for neuroscience, which could be as transformative as their GLP-1 weight-loss drugs.

Acquired Centessa Pharmaceuticals; leading the bullish sentiment around Orexin pathway drugs.

Predicted to become the largest global company driven by GLP-1/GLP-3 drugs and AI-accelerated discovery.

Positioned as a key beneficiary in the current AI market rotation cycle

High conviction pick due to the 'Obesity Trade' and the upcoming Retatrutide drug catalyst.

Top stock pick for the year with a massive regulatory capture advantage in the AI-meets-health space.

Identified as a key player in the emerging AI-meets-Pharma investment theme.

Strong long position due to expanding use cases for weight loss drugs in treating cancer and dementia.

The federal push for 'deprescribing' and reducing long-term reliance on SSRIs and psychiatric drugs poses a significant threat to prescription volumes and the maintenance-based business model.

The company's medications are now offered on the HIMS platform, effectively functioning as a partnership to expand reach for Tirzepatide.

Primary beneficiary of AI-driven biology breakthroughs and the intersection of AI and biotech.

Partnered with HIMS to distribute weight loss products, providing a significant growth catalyst.

Acting as the 'application layer' for AI in biology; utilizing massive cash flows for AI-driven genetic science.

Using GLP-1 revenues to fund AI-driven biological breakthroughs and a 1,000 GPU data center for drug discovery.

Viewed as a core portfolio anchor with potential for 2x-3x returns; currently overextended, so pullbacks to moving averages are preferred entry points.

Core portfolio anchor and long-term buy and hold; using massive cash flow to build AI data centers for drug trial data.

High-conviction trade in the weight loss/peptide sector with significant growth trajectory.

The market leader with superior current technology (Tirzepatide) and a strong triple-pathway drug (Retatrutide) in development, though the stock carries a high valuation premium.

Visser views LLY as the leader of the AI application layer, utilizing specialized models and Blackwell GPUs to drive ROI in healthcare.

Positioned as the top AI application play using proprietary clinical data and NVIDIA Blackwell GPUs to program biological responses.

Dominant player in the transformative GLP-1 sector; drugs show universal efficacy and address 200+ chronic diseases.

Clear growth trajectory driven by weight loss and healthcare trends; a favorite in the sector.

Positioned to benefit from AI integration in the healthcare sector.

Included in the healthcare sector theme expected to benefit from AI drug development.

Products related to Eli Lilly's GLP-1 weight loss drugs are a key growth lever for the telehealth space despite previous market skepticism.

Strong position in the weight-loss drug market disrupting consumer goods.

Galloway suggests a 'Long GLP-1' strategy, believing the drugs are underhyped and revolutionary for treating obesity and addictive behaviors.

Accelerating revenue growth and deep integration of AI supercomputing to transform drug discovery economics.

Referred to as 'AI Pharma' with strong gains linked to the broader tech/AI market strength.

Viewed as a bio-compute play due to massive GPU power holdings.

Strong bio/consumer drug play that recently hit new all-time highs.

Hit $1 trillion valuation milestone driven by expanded insurance coverage for Zepbound.

Launched a $500 million AI biotech fund to accelerate drug development and provides diversified exposure to the sector.

Bypassing cloud providers to spend $1 billion directly on NVIDIA GPUs to secure private compute supply.

The investigational drug Retatrutide shows high efficacy, but the company faces significant litigation risks and side-effect concerns.

Identified as a potential candidate to capture the ongoing 'peptide freight train' trend.

Frontrunner in the weight-loss drug space with potential to become the first trillion-dollar biotech company.

Highlighted as a key player in the high-demand GLP-1 weight loss market being distributed through telehealth channels.

Strategic partnership with Hims allows for distribution of branded medications; future pipeline includes next-gen drug Retatrutide.

Mentioned as a partner for branded GLP-1 distribution through the Hims & Hers platform.

Producer of GLP-1 medications and active in the Alzheimer's drug market, benefiting from the link between metabolic health and cognitive function.

Lighter enforcement on compounded alternatives creates a competitive headwind for their branded GLP-1 drugs.

Dominant player in the GLP-1 market with a recurring revenue model due to 'forever drug' nature; pipeline includes Retatrutide which may offer superior weight loss results.

Developing Retatrutide, a triple agonist showing dramatic weight loss and liver fat reduction results.

Retatrutide showing massive improvements in weight loss and liver health; company is currently supply-constrained rather than demand-constrained.

Described as a trillion-dollar safe bet in the longevity and peptide market.